Literature DB >> 26588356

Late Failing Heart Allografts: Pathology of Cardiac Allograft Vasculopathy and Association With Antibody-Mediated Rejection.

A Loupy1,2, C Toquet3, P Rouvier4, T Beuscart1, M C Bories1, S Varnous5, R Guillemain6, S Pattier7, C Suberbielle8, P Leprince5, C Lefaucheur1, X Jouven1,2,9, P Bruneval1,2,10, J P Duong Van Huyen1,2,11.   

Abstract

In heart transplantation, there is a lack of robust evidence of the specific causes of late allograft failure. We hypothesized that a substantial fraction of failing heart allografts may be associated with antibody-mediated injury and immune-mediated coronary arteriosclerosis. We included all patients undergoing a retransplantation for late terminal heart allograft failure in three referral centers. We performed an integrative strategy of heart allograft phenotyping by assessing the heart vascular tree including histopathology and immunohistochemistry together with circulating donor-specific antibodies. The main analysis included 40 explanted heart allografts patients and 402 endomyocardial biopsies performed before allograft loss. Overall, antibody-mediated rejection was observed in 19 (47.5%) failing heart allografts including 16 patients (40%) in whom unrecognized previous episodes of subclinical antibody-mediated rejection occurred 4.5 ± 3.5 years before allograft loss. Explanted allografts with evidence of antibody-mediated rejection demonstrated higher endothelitis and microvascular inflammation scores (0.89 ± 0.26 and 2.25 ± 0.28, respectively) compared with explanted allografts without antibody-mediated rejection (0.42 ± 0.11 and 0.36 ± 0.09, p = 0.046 and p < 0.0001, respectively). Antibody-mediated injury was observed in 62.1% of failing allografts with pure coronary arteriosclerosis and mixed (arteriosclerosis and atherosclerosis) pattern, while it was not observed in patients with pure coronary atherosclerosis (p = 0.0076). We demonstrate that antibody-mediated rejection is operating in a substantial fraction of failing heart allografts and is associated with severe coronary arteriosclerosis. Unrecognized subclinical antibody-mediated rejection episodes may be observed years before allograft failure. © Copyright 2015 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  clinical research/practice; coronary artery disease; heart (allograft) function/dysfunction; heart transplantation/cardiology

Mesh:

Substances:

Year:  2015        PMID: 26588356     DOI: 10.1111/ajt.13529

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  30 in total

1.  Antibody-induced vascular inflammation skews infiltrating macrophages to a novel remodeling phenotype in a model of transplant rejection.

Authors:  Xuedong Wei; Nicole M Valenzuela; Maura Rossetti; Rebecca A Sosa; Jessica Nevarez-Mejia; Gregory A Fishbein; Arend Mulder; Jayeeta Dhar; Karen S Keslar; William M Baldwin; Robert L Fairchild; Jianquan Hou; Elaine F Reed
Journal:  Am J Transplant       Date:  2020-05-22       Impact factor: 8.086

Review 2.  Complications of Cardiac Transplantation.

Authors:  Luciano Potena; Andreas Zuckermann; Francesco Barberini; Arezu Aliabadi-Zuckermann
Journal:  Curr Cardiol Rep       Date:  2018-07-10       Impact factor: 2.931

Review 3.  Recent advances in allograft vasculopathy.

Authors:  Jonathan Merola; Daniel D Jane-Wit; Jordan S Pober
Journal:  Curr Opin Organ Transplant       Date:  2017-02       Impact factor: 2.640

4.  Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.

Authors:  Sahar Salehi; Rebecca A Sosa; Yi-Ping Jin; Shoichi Kageyama; Michael C Fishbein; Enrique Rozengurt; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  Am J Transplant       Date:  2017-11-23       Impact factor: 8.086

5.  Apelin directs endothelial cell differentiation and vascular repair following immune-mediated injury.

Authors:  Andrew G Masoud; Jiaxin Lin; Abul K Azad; Maikel A Farhan; Conrad Fischer; Lin F Zhu; Hao Zhang; Banu Sis; Zamaneh Kassiri; Ronald B Moore; Daniel Kim; Colin C Anderson; John C Vederas; Benjamin A Adam; Gavin Y Oudit; Allan G Murray
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 6.  Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  J Clin Invest       Date:  2017-06-12       Impact factor: 14.808

7.  Macrophages as Effectors of Acute and Chronic Allograft Injury.

Authors:  Yianzhu Liu; Malgorzata Kloc; Xian C Li
Journal:  Curr Transplant Rep       Date:  2016-10-25

8.  Graft-Infiltrating Macrophages Adopt an M2 Phenotype and Are Inhibited by Purinergic Receptor P2X7 Antagonist in Chronic Rejection.

Authors:  C Wu; Y Zhao; X Xiao; Y Fan; M Kloc; W Liu; R M Ghobrial; P Lan; X He; X C Li
Journal:  Am J Transplant       Date:  2016-05-02       Impact factor: 8.086

9.  Discovery of non-HLA antibodies associated with cardiac allograft rejection and development and validation of a non-HLA antigen multiplex panel: From bench to bedside.

Authors:  Carrie L Butler; Michelle J Hickey; Ning Jiang; Ying Zheng; David Gjertson; Qiuheng Zhang; Ping Rao; Gregory A Fishbein; Martin Cadeiras; Mario C Deng; Hector L Banchs; Guillermo Torre; David DeNofrio; Howard J Eisen; Jon Kobashigawa; Randall C Starling; Abdallah Kfoury; Adrian Van Bakel; Gregory Ewald; Ivan Balazs; Arnold S Baas; Daniel Cruz; Reza Ardehali; Reshma Biniwale; Murray Kwon; Abbas Ardehali; Ali Nsair; Bryan Ray; Elaine F Reed
Journal:  Am J Transplant       Date:  2020-04-26       Impact factor: 8.086

10.  The effect of timing and graft dysfunction on survival and cardiac allograft vasculopathy in antibody-mediated rejection.

Authors:  Kevin J Clerkin; Susan W Restaino; Emmanuel Zorn; Elena R Vasilescu; Charles C Marboe; Donna M Mancini
Journal:  J Heart Lung Transplant       Date:  2016-05-06       Impact factor: 10.247

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.